Optogenetics: From a Nobel Prize-Winning Discovery to Vision Restoration
On 5 October 2026, the Nobel Prize in Physiology or Medicine was awarded jointly to Karl Deisseroth, Peter Hegemann and Georg Nagel for their discoveries about light-sensitive proteins and the development of optogenetics. Their work turned a basic discovery in single-celled algae into one of the most exciting technologies in modern medicine.
What this means for people with retinal conditions
For people living with retinal vision loss, this Nobel Prize is especially meaningful. Optogenetics is no longer just a promising laboratory tool. It is now being tested in people with conditions such as retinitis pigmentosa (RP) and Stargardt disease, and several clinical trials have reported encouraging improvements in vision.
What is optogenetics?
The word “optogenetics” combines “opto”, meaning light, and “genetics”, meaning the use of genes to change how cells work.
In simple terms, optogenetics adds a gene to cells that don’t normally respond to light. The gene makes a light-sensitive protein called an opsin. Once cells make this protein, they can respond to light.
The technology began with the study of channelrhodopsins. These are natural light-sensitive proteins that help a tiny green alga move towards light. Peter Hegemann and Georg Nagel discovered and described these proteins. Karl Deisseroth later showed that channelrhodopsin could be placed into the nerve cells of mammals, so scientists could switch specific nerve cells on with flashes of light.
Why is optogenetics exciting for retinal diseases?
In retinal degeneration, the light-sensing cells of the retina are lost. These are the rods and cones, also called photoreceptors. Without them, the eye can’t turn incoming light into signals for the brain.
In many people, other cells deeper in the retina survive long after the rods and cones are gone. These include bipolar cells and ganglion cells. Optogenetics uses these surviving cells and turns them into new light-detecting cells.
Key points
- It doesn’t depend on a specific gene. It could help people with many different inherited retinal conditions, not only those with one particular gene change.
- It may work in advanced vision loss. Because it uses cells that survive after the rods and cones are lost, it may help even when vision loss is severe.
- It works alongside remaining sight. It uses a different pathway from natural vision, so any natural sight a person still has may remain useful.
How does retinal optogenetics work?
The process usually has three steps:
- Delivery: the opsin gene is placed inside a harmless virus, called a viral vector. This carries it into the surviving cells of the retina.
- Production: the targeted retinal cells start making the light-sensitive opsin protein.
- Seeing: when light enters the eye, the modified cells send electrical signals along the optic nerve to the brain. Over time, the brain learns to understand these signals as visual information.
Promising optogenetic programmes
1. MCO-010 (Nanoscope Therapeutics)
MCO-010 uses a specially designed light-sensitive protein called a Multi-Characteristic Opsin (MCO). It targets the surviving bipolar cells. It’s given as a single injection into the eye, and it doesn’t depend on a specific gene change. It is being tested in both RP and Stargardt disease.
- RP (RESTORE study): people with advanced RP showed statistically significant improvements in sharpness of vision (visual acuity) compared with a placebo, or “sham”, treatment. Some participants gained about three lines on a low-vision eye chart.
- Stargardt disease (STARLIGHT study, Phase 2): improvements in visual function were reported, with a good safety profile.
This matters because traditional gene therapies only work for one specific gene change. MCO-010 has the potential to treat many different inherited retinal diseases with the same approach.
2. GS030 (GenSight Biologics)
GS030 produced the first reported case of a person regaining partial, usable vision through optogenetics.
It delivers a light-sensitive protein to the retinal ganglion cells. The person then wears special light-stimulating goggles that boost and fine-tune the visual signals.
After treatment, a man with advanced RP was reported to be able to find, identify and count objects. This was one of the first signs that optogenetics could partly restore useful vision in a blind person. GS030 remains one of the pioneering programmes that proved retinal optogenetics can work in humans.
3. Bionic Sight
Bionic Sight takes a different approach, also aimed at the retinal ganglion cells. Its system combines gene therapy with advanced image processing and computer programs that copy how the brain works. The goal is to copy the way a healthy retina codes visual information before sending it to the brain. It is still being developed, but many experts see it as one of the most advanced efforts to produce higher-quality artificial vision.
4. Ray Therapeutics
Ray Therapeutics is developing next-generation optogenetic therapies. They are designed to make cells more sensitive to light, give clearer images, and reduce the need for external devices such as goggles. The aim is for treated cells to work in more natural, everyday lighting than some earlier systems allowed. Clinical testing is still under way.
Looking ahead
Optogenetics is still being researched, and none of these treatments are available yet outside clinical trials. If you’d like to know whether research like this could be relevant to you, speak to your ophthalmologist or contact Retina South Africa.
